Wedbush starts Fibrocell Science at Outperform


Wedbush initiates coverage on Fibrocell Science (FCSC) with an Outperform rating and price target of $7.00.

"LAVIV was FDA approved for wrinkle smiles in June 2011 and is currently the only FDA-approved autologous fibroblast therapy. The company has re-focused to extend the label of azficel-T to restrictive burn and vocal cord scar and is advancing a genetically modified autologous fibroblasts product candidate for RDEB and another for the cervical spinal fusion setting," analyst Gregory Wade notes.

"Phase 2 data from the ongoing burn scar contracture study and vocal cord scar studies, both expected in H2 2014, and finalization of the pre-clinical work necessary to begin clinical studies in the epidermolysis bullosa setting by H1 2015 are catalysts that we expect will highlight the potential value of FCSC’s product and platform in important medical applications with significant unmet needs," Wade adds.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs